2021
InterShunt Announces Equity Financing Led by Solas BioVentures with participation from Arsenal Capital Management and a select group of industry executives.
January 11, 2021
Knopp Biosciences Completes Class C Financing and Elects David Adair to Board of Managers
November 11, 2020
Knopp BioSciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma
SEPTEMBER 16, 2020
Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy
JULY 15, 2020
Cryosa Completes $8.25 Million in Series A-2 Funding for Further Development of Breakthrough, Minimally Invasive Treatment for Obstructive Sleep Apnea
JUNE 25, 2020
Francis Medical Announces First Patient Enrolled in VAPOR 1 IDE Study
for Water Vapor Ablation of Prostate Cancer
JUNE 9, 2020
Baebies Announces CE Mark for Newborn Screening Assays for Galactosemia and Biotinidase Deficiency on SEEKER
MAY 27, 2020
Baebies Announces Submission of 510(k) to U.S. FDA for Glucose-6-Phosphate Dehydrogenase on FINDER
MAY 7, 2020
AEGEA Medical Receives FDA Approval for and Performs First Commercial Cases With the Mara™ Water Vapor Ablation System
MAR 24, 2020
BioStable Science & Engineering Announces Initial Closing of Series C Equity Round
FEB 25, 2020
Jerome Edwards of CardioNXT Presents on the Main Stage at the JP Morgan and Piper Sandler (formerly Piper Jaffray) Annual Healthcare Conferences
JAN 14, 2020